Adicet Bio Pretax Profit Margin Over Time
ACET Stock | USD 0.91 0.05 5.81% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Adicet Bio Performance and Adicet Bio Correlation. Adicet |
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adicet Bio. If investors know Adicet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adicet Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.70) | Quarterly Revenue Growth (1.00) | Return On Assets (0.29) | Return On Equity (0.58) |
The market value of Adicet Bio is measured differently than its book value, which is the value of Adicet that is recorded on the company's balance sheet. Investors also form their own opinion of Adicet Bio's value that differs from its market value or its book value, called intrinsic value, which is Adicet Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adicet Bio's market value can be influenced by many factors that don't directly affect Adicet Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adicet Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Adicet Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adicet Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Pretax Profit Margin Analysis
Compare Adicet Bio and related stocks such as Edgewise Therapeutics, Talaris Therapeutics, and Cullinan Oncology LLC Pretax Profit Margin Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EWTX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
CGEM | (3.5625) | (3.5625) | (3.5625) | (3.5625) | (3.5625) | (3.5625) | (3.5625) | (3.5625) | (3.5625) | (3.5625) | (3.5625) | (3.5625) | (3.5625) | (3.21) | (3.37) |
VOR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
TNYA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
BCYC | (7.9039) | (7.9039) | (7.9039) | (7.9039) | (7.9039) | (7.9039) | (7.9039) | (7.9039) | (3.1169) | (2.2362) | (4.9792) | (5.8547) | (7.8988) | (6.6432) | (6.98) |
IGMS | (207) | (207) | (207) | (207) | (207) | (207) | (207) | (207) | (207) | (207) | (207) | (207) | (207) | (115) | (121) |
GLUE | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
STOK | (8.1473) | (8.1473) | (8.1473) | (8.1473) | (8.1473) | (8.1473) | (8.1473) | (8.1473) | (8.1473) | (8.1473) | (8.1473) | (8.1473) | (8.1473) | (11.9247) | (12.52) |
AVTE | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
ACRV | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
ANEB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
AGIO | (0.7556) | (0.7556) | (0.9132) | (1.5198) | (0.8251) | (1.9914) | (2.8397) | (7.316) | (3.6661) | (3.4897) | (1.6111) | (16.2782) | (16.2782) | (13.1263) | (12.47) |
NKTX | (0.0419) | (0.0419) | (0.0419) | (0.0419) | (0.0419) | (0.0419) | (0.0419) | (0.0419) | (0.0419) | (183) | (183) | (183) | (183) | (210) | (200) |
PLRX | (0.0111) | (0.0111) | (0.0111) | (0.0111) | (0.0111) | (0.0111) | (0.0111) | (0.0111) | (0.0111) | (0.0111) | (0.9932) | (2.6035) | (12.7332) | (102) | (97.01) |
ALEC | (36.3221) | (36.3221) | (36.3221) | (36.3221) | (36.3221) | (36.3221) | (36.3221) | (8.6961) | (1.8878) | (4.9665) | (9.0164) | (0.1754) | (0.9733) | (1.2897) | (1.35) |
AADI | (0.5158) | (0.5158) | (0.5158) | (0.5158) | (0.5158) | (0.5158) | (0.5158) | (0.5158) | (0.5158) | (31.0688) | (0.2483) | (110) | (3.9769) | (2.7004) | (2.84) |
KROS | (0.1078) | (0.1078) | (0.1078) | (0.1078) | (0.1078) | (0.1078) | (0.1078) | (0.1078) | (0.1078) | (1.2336) | (2.8225) | (2.8225) | (1 K) | (1.2 K) | (1.1 K) |
Adicet Bio and related stocks such as Edgewise Therapeutics, Talaris Therapeutics, and Cullinan Oncology LLC Pretax Profit Margin description
My Equities
My Current Equities and Potential Positions
Adicet Bio | ACET |
Specialization | Health Care, Health Care Equipment & Services |
Location | Massachusetts; U.S.A |
Exchange | NASDAQ Exchange |
USD 0.91
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.